We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has accepted Sanofi’s application for expedited review of its once-daily, fixed-dose combination of insulin glargine and GLP-1 receptor agonist lixisenatide for Type 2 diabetes. Read More
Pfizer will pay $784.6 million to settle Justice Department allegations that a subsidiary overcharged Medicaid under a tentative agreement announced Tuesday. Read More
A California supplement maker is in hot water after being accused of making drug-like claims about its products and relying on improper production methods. Read More
Merck & Co. is suing German biotech and chemical giant Merck KGaA in federal court for alleged trademark infringement as part of a larger battle between the two companies over the rights to the Merck name. Read More
Novartis is joining the emerging pay-for-performance trend, inking a deal with health insurers Aetna and Cigna for its new heart failure drug Enestro. Read More